MX2023008691A - Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah). - Google Patents

Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah).

Info

Publication number
MX2023008691A
MX2023008691A MX2023008691A MX2023008691A MX2023008691A MX 2023008691 A MX2023008691 A MX 2023008691A MX 2023008691 A MX2023008691 A MX 2023008691A MX 2023008691 A MX2023008691 A MX 2023008691A MX 2023008691 A MX2023008691 A MX 2023008691A
Authority
MX
Mexico
Prior art keywords
antibodies
pah
pdgf
arterial hypertension
pulmonary arterial
Prior art date
Application number
MX2023008691A
Other languages
English (en)
Inventor
Jee Kim
Scott Macdonnell
Yinglin Gao
Bharathi Sundaram
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023008691A publication Critical patent/MX2023008691A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona anticuerpos anti-subunidad B del factor de crecimiento derivado de plaquetas (PDGF-B), y fragmentos de unión al antígeno de este, así como métodos de uso de dichos anticuerpos, o fragmentos de unión al antígeno de este, para tratar un sujeto que padece hipertensión arterial pulmonar (PAH).
MX2023008691A 2021-01-25 2022-01-25 Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah). MX2023008691A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163141030P 2021-01-25 2021-01-25
PCT/US2022/013666 WO2022159875A1 (en) 2021-01-25 2022-01-25 Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)

Publications (1)

Publication Number Publication Date
MX2023008691A true MX2023008691A (es) 2023-08-01

Family

ID=80446637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008691A MX2023008691A (es) 2021-01-25 2022-01-25 Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah).

Country Status (12)

Country Link
EP (1) EP4281475A1 (es)
JP (1) JP2024505195A (es)
KR (1) KR20230135627A (es)
CN (1) CN116964088A (es)
AU (1) AU2022210475A1 (es)
BR (1) BR112023014337A8 (es)
CA (1) CA3205846A1 (es)
CL (1) CL2023002148A1 (es)
CO (1) CO2023010900A2 (es)
IL (1) IL304505A (es)
MX (1) MX2023008691A (es)
WO (1) WO2022159875A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR20150082503A (ko) * 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
JP6946184B2 (ja) * 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法

Also Published As

Publication number Publication date
BR112023014337A2 (pt) 2023-09-26
JP2024505195A (ja) 2024-02-05
BR112023014337A8 (pt) 2024-03-05
AU2022210475A1 (en) 2023-08-10
CN116964088A (zh) 2023-10-27
EP4281475A1 (en) 2023-11-29
KR20230135627A (ko) 2023-09-25
US20220242943A1 (en) 2022-08-04
CL2023002148A1 (es) 2024-04-12
IL304505A (en) 2023-09-01
WO2022159875A1 (en) 2022-07-28
CA3205846A1 (en) 2022-07-28
CO2023010900A2 (es) 2023-08-28

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
WO2020231882A3 (en) Modified pluripotent cells
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
MX2022014598A (es) Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
EP4091453A4 (en) METHOD FOR PRODUCING A PLANT GROWTH PROMOTER, PLANT GROWTH PROMOTER AND METHOD FOR PROMOTING PLANT GROWTH
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
MX2022011156A (es) Anticuerpos anti-interleucina-33 y usos de estos.
MX2020004661A (es) Sustrato poroso sin cemento para germinacion y crecimiento de plantas elaborado de puzolanas activadas con alcali.
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2022007913A (es) Composicion oral con dulzor aumentado.
MX2022000452A (es) Proteína de fusión del anticuerpo eta y trampa de tgf-¿ y composición farmacéutica y aplicación de la misma.
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
MX2023008691A (es) Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah).
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
MX2023003086A (es) Métodos para tratar el mieloma múltiple.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.
AR124914A1 (es) Nuevo anticuerpo anti-pad4
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
MX2022012588A (es) Anticuerpo anti-cd47 y usos del mismo.
WO2020237092A3 (en) Mmp-9 antibodies and methods of use thereof